Profil Financier
Wayne Rothbaum occupe actuellement le rang #1322 du classement mondial StarFortune (secteur santé & biotech). Fortune nette estimée : $3.2 B (-$450,000 sur 24h).
Wayne Rothbaum, who founded investment firm Quogue Capital in 2001, became a wildly successful biotech investor, deploying only his own funds.
In 2012, Rothbaum cofounded and became the largest investor in cancer drug developer Acerta Pharma, whose drug Calquence was approved to treat forms of lymphoma and leukemia.
In 2016, AstraZeneca paid $4 billion for 55% of Acerta Pharma and agreed to acquire the remainder of Acerta for nearly $2.5 billion paid between 2022 and 2024.
Rothbaum is executive chair of two cancer drug firms: Kartos Therapeutics, which he cofounded in 2016, and Telios Pharma, cofounded in 2019.
Rothbaum also led a restructuring of listed biotech firm Iovance Biotherapeutics, where he is a board member and the largest shareholder, with a 9% stake.
Rothbaum's career was first described in the book "For Blood and Money: Billionaires, Biotech and the Quest for a Blockbuster Drug" published in 2023.
Rothbaum donated $300 million to SUNY Binghamton--for a sports complex and scholarships--and to Ohio State University to build housing for cancer patients.